EUVIMEDEUVIMED entdecken
MetaanalyseÜbersichtsarbeitOpen Access

Meta‐analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin

Rebecca W Zeng, Jie Ning Yong, Darren J H Tan, Clarissa E Fu, Wen Hui Lim, Jieling Xiao, Kai En Chan, Caitlyn Tan, Xin Lei Goh, Douglas Chee, Nicholas Syn iD, Eunice X Tan und 8 weitere

Alimentary Pharmacology & Therapeutics · 2023-03 · 57 (6) · 600-609

DOI: 10.1111/apt.17371 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 10.01.2023. Verfasst von Rebecca W Zeng und 19 weiteren Autor:innen. Beteiligte Einrichtung: Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Liver Neoplasms, Metformin. Die Arbeit wurde bisher 92-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, NIEHS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Emerging data suggest that statins, aspirin and metformin may protect against hepatocellular carcinoma (HCC) development. However, prior meta‐analyses were limited by heterogeneity and inclusion of studies without adequate adjustment for baseline risks.

Aim

To examine by an updated meta‐analysis the association between these medications and HCC risk.

Methods

Medline and Embase databases were searched from inception to March 2022 for studies that balanced baseline risks between study groups via propensity score matching or inverse probability of treatment weighting, that reported the impact of statins, aspirin or metformin on HCC risk. Multivariable‐adjusted hazard ratios (HRs) for HCC were pooled using a random effects model.

Results

Statin use was associated with reduced HCC risk overall (HR: 0.52; 95% CI: 0.37–0.72) (10 studies, 1,774,476), and in subgroup analyses for cirrhosis, hepatitis B/C, non‐alcoholic fatty liver disease, studies accounting for concurrent aspirin and metformin consumption and lipophilic statins. Aspirin use was associated with reduced HCC risk overall (HR: 0.48; 95% CI: 0.27–0.87) (11 studies, 2,190,285 patients) but not in studies accounting for concurrent statin and metformin use. Metformin use was not associated with reduced HCC risk overall (HR: 0.57; 95% CI: 0.31–1.06) (3 studies, 125,458 patients). Most analyses had moderate/substantial heterogeneity, except in follow‐up

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularHydroxymethylglutaryl-CoA Reductase InhibitorsLiver NeoplasmsMetforminHumansAspirinChemoprevention

Stichwörter der Autor:innen

hepatomaincidenceliver cancerprevention

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsAspirinMetformin

Autor:innen und Institutionen

  • Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore, Singapore.
  • National University Centre for Organ Transplantation, National University Health System, Singapore, Singapore.
  • Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • The Catholic University Liver Research Centre, Seoul, Korea.

ORCID-Profile: Nicholas Syn, Mark D Muthiah, Cheng Han Ng, Beom Kyung Kim, Mindie H Nguyen, Rohit Loomba, Daniel Q Huang

Förderung

  • NIDDK NIH HHS
  • NCATS NIH HHS
  • NIEHS NIH HHS
  • NIAAA NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Zeng, R. W., Yong, J. N., Tan, D. J. H., Fu, C. E., Lim, W. H., Xiao, J., Chan, K. E., Tan, C., Goh, X. L., Chee, D., Syn, N., Tan, E. X., Muthiah, M. D., Ng, C. H., Tamaki, N., Lee, S. W., Kim, B. K., Nguyen, M. H., Loomba, R., & Huang, D. Q. (2023). Meta‐analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin. Alimentary Pharmacology & Therapeutics, 57(6), 600-609. https://doi.org/10.1111/apt.17371

Vancouver

Zeng RW, Yong JN, Tan DJH, Fu CE, Lim WH, Xiao J, et al. Meta‐analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin. Alimentary Pharmacology & Therapeutics. 2023;57(6):600-609. doi:10.1111/apt.17371

BibTeX
@article{Zeng2023,
  author = {Zeng, Rebecca W and Yong, Jie Ning and Tan, Darren J H and Fu, Clarissa E and Lim, Wen Hui and Xiao, Jieling and Chan, Kai En and Tan, Caitlyn and Goh, Xin Lei and Chee, Douglas and Syn, Nicholas and Tan, Eunice X and Muthiah, Mark D and Ng, Cheng Han and Tamaki, Nobuharu and Lee, Sung Won and Kim, Beom Kyung and Nguyen, Mindie H and Loomba, Rohit and Huang, Daniel Q},
  title = {Meta‐analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2023},
  volume = {57},
  number = {6},
  pages = {600--609},
  doi = {10.1111/apt.17371}
}
Kostenlos starten →